VINDICATE 2 will be a randomised, placebo-controlled, parallel group, double-blind study of vitamin D versus placebo in otherwise optimally-managed patients with CHF due to LVSD and vitamin D deficiency (\<50nmol/L). The intervention will be a daily dose of 4000IU (100µg) per day or matching placebo for a minimum of 2 years and a maximum of 4 years.
LVSD (LVEF <50%);
stable medical and device therapy for >3mths;
25[OH]vitamin D3 <50nmol/L
At least one of: recent (<1 year) hospitalisation for HF, high dose loop diuretic requirement (>80mg daily furosemide equiv), diabetes mellitus, ischaemic aetiology
Unwilling/unable to sign consent,
Severe cognitive impairment,
Severe COPD,
Anaemia,